We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
-5.03%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$1.81B
AUM Growth
+$296M
Cap. Flow
+$503M
Cap. Flow %
27.85%
Top 10 Hldgs %
39.2%
Holding
208
New
25
Increased
78
Reduced
31
Closed
6

Top Buys

Rank Stock Value
1
DVAX
Dynavax Technologies
DVAX
+$51.6M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$45.5M
3
SYRE icon
Spyre Therapeutics
SYRE
+$42.7M
4
PLRX icon
Pliant Therapeutics
PLRX
+$36.4M
5
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$30.7M

Top Sells

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$9.97M
2
OMIC
Singular Genomics Systems, Inc. Common Stock
OMIC
+$7.23M
3
GRAL
GRAIL Inc
GRAL
+$5.83M
4
ALMS
Alumis Inc
ALMS
+$4.72M
5
SEER icon
Seer Inc
SEER
+$1.96M

Sector Composition

Rank Sector Weight
1 Healthcare 94.79%
2 Technology 1.25%
3 Communication Services 1.23%
4 Consumer Discretionary 0.99%
5 Financials 0.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BA icon
151
Boeing
BA
$185B
$1.03M 0.06%
6,068
-226
-4% -$39.1K
PAYX icon
152
Paychex
PAYX
$42.7B
$1.03M 0.06%
6,688
-285
-4% -$41.9K
MCD icon
153
McDonald's
MCD
$195B
$1.01M 0.06%
3,228
-137
-4% -$41K
AAT
154
American Assets Trust
AAT
$1.4B
$1.01M 0.06%
+50,000
New +$1.13M
AXP icon
155
American Express
AXP
$230B
$986K 0.05%
3,666
-133
-4% -$39.3K
BEAM icon
156
Beam Therapeutics
BEAM
$2.84B
$977K 0.05%
50,000
– –
ULTA icon
157
Ulta Beauty
ULTA
$24.3B
$955K 0.05%
2,606
-93
-3% -$35.4K
CVX icon
158
Chevron
CVX
$366B
$953K 0.05%
5,697
-281
-5% -$44K
HRL icon
159
Hormel Foods
HRL
$13.8B
$943K 0.05%
30,464
-1,277
-4% -$37.9K
AMZN icon
160
Amazon
AMZN
$2.96T
$931K 0.05%
4,895
-176
-3% -$38.2K
SHW icon
161
Sherwin-Williams
SHW
$89.8B
$925K 0.05%
2,648
-117
-4% -$41.1K
OPRX icon
162
OptimizeRx
OPRX
$133M
$866K 0.05%
100,000
-121,200
-55% -$741K
CLX icon
163
Clorox
CLX
$12.7B
$849K 0.05%
5,766
-248
-4% -$37.9K
UAL icon
164
United Airlines
UAL
$42.1B
$828K 0.05%
11,993
-399
-3% -$37.7K
TCRX icon
165
TScan Therapeutics
TCRX
$52M
$828K 0.05%
600,000
+482,153
+409% +$1.04M
F icon
166
Ford
F
$55.7B
$820K 0.05%
81,727
-4,022
-5% -$39.3K
GEV icon
167
GE Vernova
GEV
$264B
$792K 0.04%
2,593
-117
-4% -$40.8K
FDX icon
168
FedEx
FDX
$75.4B
$780K 0.04%
3,201
-148
-4% -$38.4K
SEE
169
DELISTED
Sealed Air
SEE
$779K 0.04%
26,946
-1,186
-4% -$38.8K
FTRE icon
170
Fortrea Holdings
FTRE
$1.75B
$755K 0.04%
100,000
– –
CAPR icon
171
Capricor Therapeutics
CAPR
$237M
$751K 0.04%
+79,100
New +$1.1M
WHR icon
172
Whirlpool
WHR
$2.82B
$736K 0.04%
8,163
-347
-4% -$36.8K
OABI icon
173
OmniAb
OABI
$447M
$720K 0.04%
300,000
– –
CNTA
174
DELISTED
Centessa Pharmaceuticals
CNTA
$719K 0.04%
+50,000
New +$818K
ENTA icon
175
Enanta Pharmaceuticals
ENTA
$400M
$699K 0.04%
126,655
– –
5 6
7
8 9

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return

Tang Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Tang Capital Management held 208 positions worth $1.81B, up 20% from $1.51B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tang Capital Management deployed $503M of net new capital in Q1 2025, opening 25 new positions and adding to 78 existing holdings. Its largest new stake was Spyre Therapeutics: 2,050,000 shares worth $33.1M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Intra-Cellular Therapies Inc., an estimated $9.97M trimmed.

  • Tang Capital Management's largest Q1 2025 buy was Spyre Therapeutics: 2,050,000 shares worth $33.1M.
  • Tang Capital Management added most to Dynavax Technologies in Q1 2025, an estimated $51.6M increase.
  • Tang Capital Management's biggest Q1 2025 reduction was Intra-Cellular Therapies Inc., cutting an estimated $9.97M.
  • Tang Capital Management fully exited Singular Genomics Systems, Inc. Common Stock in Q1 2025, selling an estimated $7.23M.
  • Tang Capital Management's ten largest holdings make up 39% of its $1.81B portfolio in Q1 2025.
  • Tang Capital Management opened 25 new positions and closed 6 in Q1 2025.
  • Tang Capital Management's portfolio value rose 20% quarter-over-quarter to $1.81B.

Based on Tang Capital Management's 13F filing for Q1 2025, filed 15 May 2025.